Guardant Health Touts Quest Deal for Shield, Guardant360 Growth and FDA Milestones at Leerink Conference

• 4 Healthcare Stocks With Massive Gains—and More to Come

Guardant Health (NASDAQ:GH) executives highlighted caller commercialized initiatives for its Shield colorectal crab screening test, continued maturation drivers for its Guardant360 therapy enactment franchise, and upcoming milestones tied to regulatory and reimbursement pathways during a league treatment hosted by Leerink Partners expert Puneet Souda.

Co-CEO AmirAli Talasaz said Guardant’s recently announced concern with Quest Diagnostics is intended to marque Shield “more broadly disposable and accessible” and has 2 superior elements: physics aesculapian grounds (EMR) integration and co-promotion.

→ Amazon Is Rising While the Market Falls—Here’s Why

• Deciphering Disruption: Inside Cathie Wood's Latest Plays

On EMR integration, Talasaz said Quest’s connectivity strategy is utilized by astir 650,000 physicians, enabling Shield to beryllium incorporated into workflows and ordered much easily. He added that the institution expects this to summation ordering extent among accounts that already usage Quest systems.

On co-promotion, Talasaz said Quest’s superior attraction transmission volition item and amended physicians alongside Guardant’s ain commercialized efforts. However, helium emphasized that Guardant is being blimpish successful its fiscal planning, stating the company’s anterior guidance for 2026 did not see immoderate incremental publication from Quest’s co-promotion to Shield measurement oregon revenue. Talasaz said the concern could person much interaction successful the 2nd fractional of the year, with the institution looking to supply updates arsenic information emerges.

→ Home Depot Stock Keeps Falling—Analysts Say the Upside Is Still There

• 3 Fast-Growing Stocks Analysts See Doubling successful Price

In discussing Guardant360, Co-CEO Helmy Eltoukhy described aggregate drivers down the franchise’s growth, including broader adoption of liquid biopsy and expanding objective applications. He said the tract is inactive not afloat penetrated adjacent for “one clip per lifetime” use, estimating penetration astir 30% to 40% for that archetypal usage.

Eltoukhy besides pointed to expanding trial capabilities—such arsenic utilizing methylation signals and different level enhancements to amended qualify tumor biology and histology—as helping determination liquid biopsy into broader utility. He framed different semipermanent maturation lever arsenic repeated investigating implicit the people of treatment, enabled by the expanding fig of therapeutic options and the request to way tumor evolution.

→ Eli Lilly’s Employer Push Could Unlock New GLP-1 Demand